Linked Life Data

21141868

Source:http://linkedlifedata.com/resource/pubmed/id/21141868

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-7
pubmed:abstractText
In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1535-3907
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
51-7
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare.
pubmed:affiliation
Thoracic Surgery, Niizashiki Chuo General Hospital, Saitama, Japan.
pubmed:publicationType
Journal Article